A Study of Navenibart in Participants With Hereditary Angioedema

Exclusion Criteria

• •Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor deficiency, HAE with normal C1-INH (also known as HAE type 3), idiopathic angioedema, or angioedema associated with urticaria.
• •Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to washout prior to entering the Run-In Period).
• •1. Tranexamic acid, oral danazol, oral stanazolol, and oral oxandrolone within 3 days prior to Run-In
• •2. Plasma-derived C1INH for LTP within 14 days prior to Run-In
• •3. Berotralstat within 21 days prior to Run-In
• •4. Lanadelumab within 70 days prior to Run-In
• •5. Garadacimab within 90 days prior to Run-In